The Russian retail market for drugs used to treat bronchial asthma and COPD (EphMRA group R03) reached RUB 25.7 billion in 2025 (at retail prices, including VAT). Compared to the previous year, the ruble sales volume increased by nearly 12%. In total, Russians purchased over 44.6 million packages of such drugs last year — physical demand grew by 9% over the year. It is important to note that over the past three years, there has been a steady increase in the consumption of antiasthma drugs in the retail pharmaceutical market segment, with domestic drug sales dynamics outpacing the growth rates of imported products. In 2025, the sales volume of domestically produced drugs in the category increased by 21% in rubles compared to the previous year, while sales of imported drugs grew by 11%.

The antiasthma drug market is characterized by pronounced seasonality: peak consumption typically occurs in the spring and autumn months, rising towards December, followed by a decline in January–February. However, the beginning of 2026 was also marked by a decrease in demand compared to the same period last year, with demand falling by 3%. In the first two months of the current year, approximately 7 million packages worth RUB 4.2 billion were sold in pharmacies, with the decline in demand affecting both domestic and imported drugs.

According to the database "Retail Audit of Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, domestically produced drugs for the treatment of bronchial asthma and COPD accounted for approximately 33.7% of the total physical sales volume in the group last year. Over several years, the share of Russian drugs in the group has increased by 6.5 percentage points (p.p.); in 2022, they accounted for only 27.2% of sales in packages. The ruble figures are more modest: in 2025, Russian manufacturers held a 15.4% share of the value volume of the antiasthma drug market, demonstrating a steady annual increase in share of 1 p.p. Here, the price factor plays a role — Russian products are, on average, 2.5 times cheaper than foreign equivalents. The average cost of one package of a domestically produced drug in this category did not exceed RUB 290 last year, while a package of an imported product cost approximately RUB 730.

Overall, by the end of 2025, there were over 100 trademarks in retail, produced by 59 corporations. Notably, just under half of consumer spending was concentrated on only three leading brands: Pulmicort, Berodual, and Symbicort from AstraZeneca and Boehringer Ingelheim. The leading brand in the category, Pulmicort from AstraZeneca, accounts for 23.7% of all sales. Second place in the ranking remains with Berodual from Boehringer Ingelheim (14.4% share). Third place is held by Symbicort (AstraZeneca), with an 11% share of value sales. The highest sales growth in monetary terms in the top ten was recorded for the Italian brand Foster from Chiesi (+28%). The only brand in the top ten that showed a decline in sales was Seretide from GSK, with spending on it decreasing by 3% and physical consumption decreasing by 6%.

Fig. Structure of the Russian Retail Market for Asthma and COPD Drugs (EphMRA Group R03) by Imported/Domestic Type in 2022–2025 and January–February 2026